The mechanisms by which doxorubicin activates NF-κB remain unclear, however previously studied mechanisms include activation via the IKK complex, PI3K dependent pathway, and c-Abl kinase activity in breast cancer cells [67, 68]. The gene discussed is NFKB1; the disease is breast cancer.